Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia

Blood Advances - Tập 3 Số 3 - Trang 339-349 - 2019
Hassan Awada1, Yasunobu Nagata1, Abhinav Goyal1, Mohammad Asad1, Bhumika J. Patel2, Cassandra M. Hirsch1, Teodora Kuzmanovic1, Yihong Guan1, Bartlomiej Przychodzen1, Mai Aly1, Vera Ademà1, Wenyi Shen1, Louis Williams1, Aziz Nazha2, Mohamed E. Abazeed1, Mikkael A. Sekeres2, Tomas Radivoyevitch3, Torsten Haferlach4, Babal K. Jha1, Valeria Visconte1, Jarosław P. Maciejewski1,2
1Department of Translational Hematology and Oncology Research, Lerner Research Institute,
2Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, and
3Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; and
4MLL Munich Leukemia Laboratory, Munich, Germany

Tóm tắt

Abstract Somatic TET2 mutations (TET2MT) are frequent in myeloid neoplasia (MN), particularly chronic myelomonocytic leukemia (CMML). TET2MT includes mostly loss-of-function/hypomorphic hits. Impaired TET2 activity skews differentiation of hematopoietic stem cells toward proliferating myeloid precursors. This study was prompted by the observation of frequent biallelic TET2 gene inactivations (biTET2i) in CMML. We speculated that biTET2i might be associated with distinct clinicohematological features. We analyzed TET2MT in 1045 patients with MN. Of 82 biTET2i cases, 66 were biTET2MT, 13 were hemizygous TET2MT, and 3 were homozygous TET2MT (uniparental disomy); the remaining patients (denoted biTET2− hereafter) were either monoallelic TET2MT (n = 96) or wild-type TET2 (n = 823). Truncation mutations were found in 83% of biTET2i vs 65% of biTET2− cases (P = .02). TET2 hits were founder lesions in 72% of biTET2i vs 38% of biTET2− cases (P < .0001). In biTET2i, significantly concurrent hits included SRSF2MT (33%; P < .0001) and KRAS/NRASMT (16%; P = .03) as compared with biTET2−. When the first TET2 hit was ancestral in biTET2i, the most common subsequent hits affected a second TET2MT, followed by SRSF2MT, ASXL1MT, RASMT, and DNMT3AMT. BiTET2i patients without any monocytosis showed an absence of SRSF2MT. BiTET2i patients were older and had monocytosis, CMML, normal karyotypes, and lower-risk disease compared with biTET2− patients. Hence, while a second TET2 hit occurred frequently, biTET2i did not portend faster progression but rather determined monocytic differentiation, consistent with its prevalence in CMML. Additionally, biTET2i showed lower odds of cytopenias and marrow blasts (≥5%) and higher odds of myeloid dysplasia and marrow hypercellularity. Thus, biTET2i might represent an auxiliary assessment tool in MN.

Từ khóa


Tài liệu tham khảo

Vardiman, 2008, Chronic myelogenous leukaemia, BCR-ABL1-positive, WHO Classification of Tumours of Haematopoietic and Lymphoid tissues, 4th ed., 32

Yan, 2006, A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis, Nat Med, 12, 945, 10.1038/nm1443

Ayton, 2001, Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins, Oncogene, 20, 5695, 10.1038/sj.onc.1204639

Fröhling, 2005, Genetics of myeloid malignancies: pathogenetic and clinical implications, J Clin Oncol, 23, 6285, 10.1200/JCO.2005.05.010

Pabst, 2008, Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia, J Clin Oncol, 26, 5088, 10.1200/JCO.2008.16.5563

Hayashi, 2017, Myeloid neoplasms with germ line RUNX1 mutation, Int J Hematol, 106, 183, 10.1007/s12185-017-2258-5

Sood, 2017, Role of RUNX1 in hematological malignancies, Blood, 129, 2070, 10.1182/blood-2016-10-687830

Zhang, 2015, Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy, Nat Genet, 47, 180, 10.1038/ng.3177

Noetzli, 2015, Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia, Nat Genet, 47, 535, 10.1038/ng.3253

Polprasert, 2015, Inherited and somatic defects in DDX41 in myeloid neoplasms, Cancer Cell, 27, 658, 10.1016/j.ccell.2015.03.017

Al Seraihi, 2018, GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML, Leukemia, 32, 2502, 10.1038/s41375-018-0134-9

Nishiyama, 2018, Mutation analysis of therapy-related myeloid neoplasms, Cancer Genet, 222-223, 38, 10.1016/j.cancergen.2018.02.006

Papaemmanuil, 2011, Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts, N Engl J Med, 365, 1384, 10.1056/NEJMoa1103283

Cazzola, 2013, The genetic basis of myelodysplasia and its clinical relevance, Blood, 122, 4021, 10.1182/blood-2013-09-381665

Malcovati, 2009, Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Blood, 114, 3538, 10.1182/blood-2009-05-222331

Szpurka, 2009, UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation, Leukemia, 23, 610, 10.1038/leu.2008.249

Mughal, 2015, An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms, Haematologica, 100, 1117, 10.3324/haematol.2014.114660

Bejar, 2011, Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, 364, 2496, 10.1056/NEJMoa1013343

Li, 2011, Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies, Blood, 118, 4509, 10.1182/blood-2010-12-325241

Pan, 2017, Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells, Nat Commun, 8, 15102, 10.1038/ncomms15102

Ko, 2015, TET proteins and 5-methylcytosine oxidation in hematological cancers, Immunol Rev, 263, 6, 10.1111/imr.12239

Ko, 2010, Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature, 468, 839, 10.1038/nature09586

Nakajima, 2014, TET2 as an epigenetic master regulator for normal and malignant hematopoiesis, Cancer Sci, 105, 1093, 10.1111/cas.12484

Bowman, 2017, TET2 in normal and malignant hematopoiesis, Cold Spring Harb Perspect Med, 7, a026518, 10.1101/cshperspect.a026518

Hirsch, 2018, Consequences of mutant TET2 on clonality and subclonal hierarchy, Leukemia, 32, 1751, 10.1038/s41375-018-0150-9

Tefferi, 2008, Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms, Leukemia, 22, 14, 10.1038/sj.leu.2404955

Haferlach, 2014, Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Leukemia, 28, 241, 10.1038/leu.2013.336

Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, 122, 3616, 10.1182/blood-2013-08-518886

Jankowska, 2009, Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms, Blood, 113, 6403, 10.1182/blood-2009-02-205690

Langemeijer, 2009, TET proteins in malignant hematopoiesis, Cell Cycle, 8, 4044, 10.4161/cc.8.24.10239

Walter, 2013, Clonal diversity of recurrently mutated genes in myelodysplastic syndromes, Leukemia, 27, 1275, 10.1038/leu.2013.58

Thota, 2014, Genetic alterations of the cohesin complex genes in myeloid malignancies, Blood, 124, 1790, 10.1182/blood-2014-04-567057

Nagata, 2016, Variegated RHOA mutations in adult T-cell leukemia/lymphoma, Blood, 127, 596, 10.1182/blood-2015-06-644948

Nannya, 2005, A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays, Cancer Res, 65, 6071, 10.1158/0008-5472.CAN-05-0465

Yamamoto, 2007, Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays, Am J Hum Genet, 81, 114, 10.1086/518809

da Silva, 2017, Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome, J Clin Pathol, 70, 435, 10.1136/jclinpath-2016-204023

Shaffer, 2005, SCN 2005: An International System for Human Cytogenetic Nomenclature

Langemeijer, 2009, Acquired mutations in TET2 are common in myelodysplastic syndromes, Nat Genet, 41, 838, 10.1038/ng.391

Delhommeau, 2009, Mutation in TET2 in myeloid cancers, N Engl J Med, 360, 2289, 10.1056/NEJMoa0810069

Kosmider, 2009, TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs), Blood, 114, 3285, 10.1182/blood-2009-04-215814

Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med, 20, 1472, 10.1038/nm.3733

Busque, 2012, Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis, Nat Genet, 44, 1179, 10.1038/ng.2413

Tefferi, 2009, Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML, Leukemia, 23, 1343, 10.1038/leu.2009.59

Patel, 2017, Genomic determinants of chronic myelomonocytic leukemia, Leukemia, 31, 2815, 10.1038/leu.2017.164

Meggendorfer, 2012, SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML), Blood, 120, 3080, 10.1182/blood-2012-01-404863

Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262

Santos, 2012, Laboratory diagnosis of chronic myelomonocytic leukemia and progression to acute leukemia in association with chronic lymphocytic leukemia: morphological features and immunophenotypic profile, Rev Bras Hematol Hemoter, 34, 242, 10.5581/1516-8484.20120058

Makishima, 2017, Dynamics of clonal evolution in myelodysplastic syndromes, Nat Genet, 49, 204, 10.1038/ng.3742

Chen, 2017, Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis, Oncotarget, 8, 1944, 10.18632/oncotarget.13719

Zhang, 2017, Acetylation enhances TET2 function in protecting against abnormal DNA methylation during oxidative stress, Mol Cell, 65, 323, 10.1016/j.molcel.2016.12.013

Thông tin
Thông tin xuất bản

Blood Advances

Tập 3 Số 3

339-349

Thông tin tác giả